Harnessing SARS-CoV-2-specific CD8^(+)T cells to kill target tumor cells for cancer immunotherapy

作     者：Keunok Jung Deok-Han Ko Jeong-Yun Jang Young Rong Kim Jung Yeon Heo Yong-Sung Kim 

作者机构：Department of Allergy and Clinical ImmunologyAjou University School of MedicineSuwonRepublic of Korea Department of Molecular Science and TechnologyAjou UniversitySuwonRepublic of Korea Department of Infectious DiseasesAjou University School of MedicineSuwonRepublic of Korea 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2024年第44卷第1期

页      面：173-177页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the Samsung Future Technol-ogy Center(SRFCMA1802-09) the Korea Health Technology R&D Project(HR22C173402)through the Korea Health Industry Development Institute(KHIDI)funded by the Ministry of Health and Welfare 

主　　题：acute respiratory immunotherapy 

摘      要：Dear Editor,During the coronavirus disease 2019(COVID-19)pan-demic era,many individuals were naturally infected with or vaccinated against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),resulting in the presence of cytotoxic CD8^(+)T cells(CTLs)specific to SARS-CoV-2 antigens,including the spike protein[1,2].